insights+Analyses Published

We're attuned to (often ahead of) the key issues facing the market. It's about arming investors, consumers, and businesses with the information they need to make sound decisions.
Articles filtered by:

Gregory Asciolla, Matthew Perez

Recent Posts

ThinkstockPhotos-71262728-1
INSIGHTS & ANALYSES

FDA Risk-Evaluation Guidance Unlikely To Help Generics

Gregory Asciolla and Matthew Perez discuss the U.S. FDA’s guidances concerning risk evaluation and mitigation strategies and the likely minimal ...

Tuesday, June 12, 2018

by Gregory Asciolla, Matthew Perez
CREATEsActArticle_AsciollaPerez
INSIGHTS & ANALYSES

Creating a Partial Solution to Delayed Generic Competition

This article explores the benefits and limitations of the proposed legislation, the CREATES Act of 2016. A bipartisan group of U.S. senators recently ...

Friday, June 24, 2016

by Gregory Asciolla, Matthew Perez
MAIN-stacked-pills
INSIGHTS & ANALYSES

“Shall We Dance?”— Biologic-Biosimilar Competition Under the Biologics Price Competition and Innovation Act

As more biosimilar applications are filed, courts will inevitably face the novel and complex issues posed by the BPCIA with increasing frequency. I. ...

Monday, December 14, 2015

by Gregory Asciolla, Matthew Perez
1